Metabolomes of mitochondrial diseases and inclusion body myositis patients : treatment targets and biomarkers

Show full item record



Buzkova , J , Nikkanen , J , Ahola , S , Hakonen , A H , Sevastianova , K , Hovinen , T , Yki-Järvinen , H , Pietiläinen , K H , Lönnqvist , T , Velagapudi , V , Carroll , C J & Suomalainen , A 2018 , ' Metabolomes of mitochondrial diseases and inclusion body myositis patients : treatment targets and biomarkers ' , EMBO molecular medicine , vol. 10 , no. 12 , 9091 .

Title: Metabolomes of mitochondrial diseases and inclusion body myositis patients : treatment targets and biomarkers
Author: Buzkova, Jana; Nikkanen, Joni; Ahola, Sofia; Hakonen, Anna H.; Sevastianova, Ksenia; Hovinen, Topi; Yki-Järvinen, Hannele; Pietiläinen, Kirsi H.; Lönnqvist, Tuula; Velagapudi, Vidya; Carroll, Christopher J.; Suomalainen, Anu
Contributor organization: Research Programme for Molecular Neurology
Research Programs Unit
University of Helsinki
Anu Wartiovaara / Principal Investigator
Department of Medicine
University Management
Diabetes and Obesity Research Program
Endokrinologian yksikkö
Children's Hospital
Lastenneurologian yksikkö
Institute for Molecular Medicine Finland
Helsinki Institute of Life Science HiLIFE
Department of Neurosciences
Neuroscience Center
HUS Internal Medicine and Rehabilitation
HUS Abdominal Center
HUS Children and Adolescents
Date: 2018-12
Language: eng
Number of pages: 15
Belongs to series: EMBO molecular medicine
ISSN: 1757-4676
Abstract: Mitochondrial disorders (MDs) are inherited multi-organ diseases with variable phenotypes. Inclusion body myositis (IBM), a sporadic inflammatory muscle disease, also shows mitochondrial dysfunction. We investigated whether primary and secondary MDs modify metabolism to reveal pathogenic pathways and biomarkers. We investigated metabolomes of 25 mitochondrial myopathy or ataxias patients, 16 unaffected carriers, six IBM and 15 non-mitochondrial neuromuscular disease (NMD) patients and 30 matched controls. MD and IBM metabolomes clustered separately from controls and NMDs. MDs and IBM showed transsulfuration pathway changes; creatine and niacinamide depletion marked NMDs, IBM and infantile-onset spinocerebellar ataxia (IOSCA). Low blood and muscle arginine was specific for patients with m.3243A>G mutation. A four-metabolite blood multi-biomarker (sorbitol, alanine, myoinositol, cystathionine) distinguished primary MDs from others (76% sensitivity, 95% specificity). Our omics approach identified pathways currently used to treat NMDs and mitochondrial stroke-like episodes and proposes nicotinamide riboside in MDs and IBM, and creatine in IOSCA and IBM as novel treatment targets. The disease-specific metabolic fingerprints are valuable "multi-biomarkers" for diagnosis and promising tools for follow-up of disease progression and treatment effect.
Subject: biomarker
inclusion body myositis
mitochondrial diseases
3111 Biomedicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
e9091.full.pdf 2.618Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record